FDA Approves AstraZeneca And Daiichi Sankyo's Enhertu For Solid Tumors Treatment

(RTTNews) - The U.S. Food and Drug Administration approved AstraZeneca (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) Enhertu (fam-trastuzumab deruxtecan-nxki) for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received https://www.nasdaq.com/articles/fda-approves-astrazeneca-and-daiichi-sankyos-enhertu-for-solid-tumors-treatment